多发性骨髓瘤可测量残留病评估的挑战与机遇
该综述讨论多发性骨髓瘤治疗反应评估依赖血清/尿副蛋白、骨髓形态和免疫组化,随着治疗进步完全缓解变常见,需检测更小残留病。MRD主要用流式细胞术和二代测序评估,先进方法灵敏度接近1/10^6细胞。文章讨论MRD用于指导管理的现有挑战及研究机遇。
要点
- MM反应评估依赖血清/尿副蛋白、骨髓形态和免疫组化。
- MRD主要用流式细胞术和二代测序评估,先进方法灵敏度接近1/10^6细胞。
- 综述讨论MRD指导MM管理的挑战与开放研究问题。
核心结论
- MRD评估在多发性骨髓瘤中面临挑战,同时存在融入临床实践的研究机遇。
研究设计与样本
- 综述,讨论多发性骨髓瘤MRD评估的现有挑战与研究机遇。
主要发现
- 治疗进步使新诊断患者完全缓解频繁,需识别更小残留病并理解其预后和治疗意义。
- MRD主要用流式细胞术和二代测序评估,先进方法灵敏度接近1/10^6细胞。
关键数值与推荐
- 先进MRD检测方法灵敏度接近1/10^6细胞。
临床怎么用
- MRD正更常规地纳入多发性骨髓瘤临床实践,用于指导患者管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment response assessment in multiple myeloma (MM) relies on the detection of paraprotein in serum and/or urine, bone marrow morphology and immunohistochemistry. With remarkable advances in therapy, particularly in the newly diagnosed setting, achievement of complete remission became frequent, creating the need to identify smaller amounts of residual disease and understand their prognostic and therapeutic implications. Measurable residual disease (MRD) can be assessed primarily by flow cytometry and next generation sequencing and state-of-the-art assays have sensitivity approaching 1 in 106 cells. This review discusses the existing challenges in utilizing MRD to inform management of MM and highlights open research questions and opportunities as MRD is more routinely incorporated into clinical practice for patients with MM.
引用
- Bal S, Weaver A, Cornell RF, et al. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. Br J Haematol. 2019. PMID: 31364160. doi:10.1111/bjh.16130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。